Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

A new study found users who take the drug-made by Pfizer- for a year or more are 3.5 times more likely to develop a meningioma, the most common type of brain tumour.

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

The second healthcare sector IPCEI – approving up to €403 million of State aid by five Member States, including France, ...

More than 30 years ago, when Jean-Pascal Tricoire first came to China, his friends gave him the Chinese ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

WASHINGTON] Crypto companies and advocates of digital assets boosted their lobbying this year to ensure passage of landmark ...